Solid Tumor NGS Panel
SpecimenFFPE tissue / ctDNA (planned)TAT5-10 business days (target)
Broad genomic profiling focused on actionable alterations to support targeted therapy selection and trial matching.
VEX DIAGNOSTICS
Test Menu
A scalable catalog structure ready to evolve into a real portfolio backed by validation documents, specimen requirements, and ordering workflows.
Catalog
Browse tests
Placeholder test catalog with realistic structure and language.
For shareholder preview: categories, indications, specimen types, and turnaround placeholders.
Category
Showing 7 tests across all categories.
Comprehensive Tumor Profiling
Heme Malignancy Panel
SpecimenWhole blood / bone marrowTAT5-10 business days (target)
Myeloid/lymphoid-focused variant detection and interpretation aligned to clinical decision pathways.
Targeted Biomarkers
MSI
SpecimenFFPE tissueTAT3-5 business days (target)
Microsatellite instability assessment to inform immunotherapy eligibility and clinical context.
TMB
SpecimenFFPE tissueTAT5-10 business days (target)
Tumor mutational burden estimate as a supportive biomarker for immunotherapy strategy discussions.
Fusion Detection
SpecimenFFPE tissue / RNATAT5-10 business days (target)
Fusion discovery and reporting optimized for therapeutically relevant targets.
Advanced LDTs
Ultra-sensitive Variant Detection
SpecimenctDNA (planned)TAT5-10 business days (target)
Designed for low allele frequency detection use cases where sensitivity and QC discipline are critical.
Minimal Residual Disease (MRD) Pathway
SpecimenTo be definedTATTo be defined
A future-ready program concept for longitudinal monitoring workflows and data-driven reporting.
Partner With Vex
Bring clarity to complex oncology decisions
Discuss test offerings, reporting expectations, and partnership models.